Lineage Cell Therapeutics (LCTX) Interest Expenses (2010 - 2026)

Lineage Cell Therapeutics' Interest Expenses history runs 16 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 3747.87% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $11.7 million, a 848.47% increase from a year earlier, with the FY2025 full-year figure at $89.4 million, up 3.6% from the prior year.
• Interest Expenses grew to $11.7 million in Q1 2026 per LCTX's latest filing, from -$727000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $15.1 million in Q3 2025 and bottomed at -$727000.0 in Q4 2025.
• The 5-year median for Interest Expenses is $453000.0 (2023), against an average of $2.0 million.
• Across the five-year window, Interest Expenses sank 312.5% in 2022 and jumped 3747.87% in 2026, its largest moves.
• Year by year, Interest Expenses stood at -$527000.0 in 2022, then declined by 20.11% to -$633000.0 in 2023, then decreased by 12.64% to -$713000.0 in 2024, then retreated by 1.96% to -$727000.0 in 2025, then jumped by 1714.31% to $11.7 million in 2026.
• Per Business Quant, the three latest LCTX Interest Expenses figures stand at $11.7 million (Q1 2026), -$727000.0 (Q4 2025), and $15.1 million (Q3 2025).